Drawing for RISE, STABILIZE AND THRIVE

USPTO serial 98689783

RISE, STABILIZE AND THRIVE

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
COLLIS, BRIAN J
Law office
TMO LAW OFFICE 129

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with RISE, STABILIZE AND THRIVE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Katharyn Bond

Katharyn Bond Kat Bond Law21C Orinda Way, #172Orinda, CA 94563United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of addiction to and abuse of alcohol, opiates, narcotics, food, sex, gambling, and other addictive or habit forming substances or behavior, for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, obesity disease, diabetes disease, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of a subcutaneous drug delivery device sold filled with sustainable release pharmaceutical preparations used in the treatment of addiction to and abuse of alcohol, opiates, narcotics, food, sex, gambling, and other addictive or habit forming substances or behavior, central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, obesity disease, diabetes disease, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; pharmaceuticals, namely, implantable drug delivery system comprised of a subcutaneous drug delivery device sold filled with a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction and diabetes disease; pharmaceuticals, namely, implantable drug delivery system comprised of a subcutaneous drug delivery device sold filled with a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening disease; Vitamins; Collagen for medical purposes; Hormone replacement therapy preparationsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Oct 14, 2025MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 14, 2025ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 27, 2025XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Jun 27, 2025XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Mar 28, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 28, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 28, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 24, 2025DOCKASSIGNED TO EXAMINER—
Feb 23, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 12, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance